Frequency Allocation for Hearing Loss
Trial Summary
Will I have to stop taking my current medications?
The trial protocol does not specify whether you need to stop taking your current medications.
What data supports the effectiveness of the treatment for hearing loss?
Research on cochlear 'dead regions' suggests that enhancing frequency discrimination near these areas can improve hearing, which may support the use of customized frequency mapping in the treatment. Additionally, studies on high frequency audiometry indicate its potential for early detection of hearing issues, suggesting that frequency allocation adjustments could be beneficial.12345
How does the Experimental Frequency Allocation Table treatment differ from other treatments for hearing loss?
The Experimental Frequency Allocation Table treatment is unique because it customizes frequency mapping based on individual anatomy, potentially enhancing frequency discrimination by targeting specific 'dead regions' in the cochlea. This approach differs from standard treatments by focusing on personalized frequency allocation to improve hearing outcomes.25678
What is the purpose of this trial?
This study will examine experienced, bimodal cochlear implant (CI) patients who receive an alternative frequency allocation table (FAT) to determine how it improves sound quality, device satisfaction, and speech perception abilities with respect to the standard default FAT. The goal of this study is to investigate how improving place-pitch mismatch in bimodal CI users affects 1) sound quality, 2) satisfaction, and 3) speech perception.
Research Team
Mario A. Svirsky, PhD
Principal Investigator
NYU Langone Health
Eligibility Criteria
This trial is for people with mixed conductive and sensorineural hearing loss, deafness, or general hearing loss who already use a cochlear implant (CI). Specific eligibility criteria are not provided, but typically participants must meet certain health standards and agree to follow the study procedures.Inclusion Criteria
Exclusion Criteria
Timeline
Screening
Participants are screened for eligibility to participate in the trial
Experimental FAT Adaptation
Participants are fitted with an experimental frequency allocation table (FAT) and undergo a 1-month adaptation period
Standard FAT Re-adaptation
Participants undergo a 1-month re-adaptation to the standard frequency allocation table (FAT)
Follow-up
Participants are monitored for safety and effectiveness after treatment
Treatment Details
Interventions
- Experimental frequency allocation table (FAT) - 438 Hz
- Standard FAT - 188 Hz
Find a Clinic Near You
Who Is Running the Clinical Trial?
NYU Langone Health
Lead Sponsor
National Institute on Deafness and Other Communication Disorders (NIDCD)
Collaborator